'New' Not Always 'better' With Drugs
Research into 39 proprietary medicinal products (PMPs) launched on the German market in 2009 and 2010 shows that there were frequently insufficient data available on efficacy when approval was granted.
The legal requirements of the licensing procedure have never yet required direct data comparing a new drug to a commercially available drug.
The researchers' evaluations also show that for around half of approvals the only trials presented compared the new drug with a placebo, not an effective comparator drug. This can give rise to room for interpretation regarding pricing when new drugs are marketed.
The authors do not even rule out the possibility that these more expensive PMPs may actually be inferior to the alternatives already on the market.
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
International, Deutsches Aerzteblatt. "'New' Not Always 'better' With Drugs." Medical News Today. MediLexicon, Intl., 6 Mar. 2012. Web.
23 Apr. 2017. <http://www.medicalnewstoday.com/releases/242463.php>
International, D. (2012, March 6). "'New' Not Always 'better' With Drugs." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.